Chronic hepatitis C is a curable disease. The traditional dual therapy with pegylated interferon-a with ribavirin achieves a relatively acceptable eradication rate. However, there was still a significant portion of patients who could not achieve this goal. On the other hand, the one-year treatment duration with significant side effect would really become a limitation for the patients to seek for the medical help. Recently, a resolution of the three-dimensional structures of several Hepatitis C virus (HCV) proteins, together with the development of replicative cell culture systems, has led to the identification of a number of potential targets for direct-acting antiviral agents (DAA). Numerous families of drugs that potently inhibit the HCV life cycle in vitro have been identified, and some of these molecules have reached early to late clinical development. Two NS3-4A protease inhibitors, telaprevir and boceprevir, were approved in Europe and the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1. A number of other DAAs are at the clinical developmental stage. They include second-wave, first-generation, and second-generation NS3-4A protease inhibitors, nucleoside/nucleotide analogue inhibitors, and non-nucleoside inhibitors of HCV RNA-dependent RNA polymerase, inhibitors of nonstructural protein 5A and host-targeted agents, such as cyclophilin A inhibitors and microRNA-122 antagonists. Most of these developing drugs are still adopted the combination with pegylated interferon in order to increase the successful rate and shorten the treatment duration though a new trend of strategy is focusing on a interferon-free regimens. In this talk, an overview about the IFN-containing DAAs regimen would be discussed.